Quest Diagnostics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 3/6
Quest Diagnostics şirketinin kazançları yıllık ortalama -5.7% oranında azalırken, Healthcare sektörünün kazançları yıllık 5.4% oranında artan oldu. Gelirler yıllık ortalama 3.1% oranında artan oldu. Quest Diagnostics şirketinin öz sermaye getirisi 12.9% olup, net marjı 8.8% dir.
Anahtar bilgiler
-5.7%
Kazanç büyüme oranı
-1.8%
EPS büyüme oranı
Healthcare Sektör Büyümesi | 8.5% |
Gelir büyüme oranı | 3.1% |
Özkaynak getirisi | 12.9% |
Net Marj | 8.8% |
Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Oct 25Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Oct 24Why Investors Shouldn't Be Surprised By Quest Diagnostics Incorporated's (NYSE:DGX) P/E
Oct 23Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Oct 15These 4 Measures Indicate That Quest Diagnostics (NYSE:DGX) Is Using Debt Reasonably Well
Aug 30Should You Think About Buying Quest Diagnostics Incorporated (NYSE:DGX) Now?
Aug 12Quest Diagnostics: Beat Down After Beating Q2 Estimates
Jul 28The Price Is Right For Quest Diagnostics Incorporated (NYSE:DGX)
Jul 12Quest Diagnostics: On A Quest For Growth
Jul 12Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns
May 14Quest Diagnostics: Let's Keep Waiting
May 08Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year
Mar 15Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75
Feb 06Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Feb 05Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 11Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price
Dec 24Quest Diagnostics: Market Overreaction Creates Investment Opportunity
Dec 08Is There Now An Opportunity In Quest Diagnostics Incorporated (NYSE:DGX)?
Dec 06Quest Diagnostics' (NYSE:DGX) Returns Have Hit A Wall
Nov 18Quest Diagnostics: Moving Past Covid
Oct 25Here's Why Quest Diagnostics (NYSE:DGX) Can Manage Its Debt Responsibly
Sep 25What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Sep 04Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
Aug 15Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
Aug 13Quest Diagnostics Incorporated (NYSE:DGX) Shares Could Be 46% Below Their Intrinsic Value Estimate
Jul 11Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Jun 09Quest Diagnostics: Healthier Diagnosis
May 30Is It Time To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)?
May 24Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
May 09An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 24% Undervalued
Mar 22What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Feb 19Why Quest Diagnostics Isn't A 'Buy', My Oh My
Feb 14Quest Diagnostics' (NYSE:DGX) Upcoming Dividend Will Be Larger Than Last Year's
Feb 05Gelir ve Gider Dağılımı
Quest Diagnostics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Sep 24 | 9,539 | 838 | 1,681 | 0 |
30 Jun 24 | 9,346 | 836 | 1,624 | 0 |
31 Mar 24 | 9,287 | 842 | 1,621 | 0 |
31 Dec 23 | 9,252 | 850 | 1,615 | 0 |
30 Sep 23 | 9,297 | 759 | 1,748 | 0 |
30 Jun 23 | 9,488 | 790 | 1,825 | 0 |
31 Mar 23 | 9,603 | 789 | 1,832 | 0 |
31 Dec 22 | 9,883 | 942 | 1,818 | 0 |
30 Sep 22 | 10,294 | 1,230 | 1,736 | 0 |
30 Jun 22 | 10,582 | 1,479 | 1,705 | 0 |
31 Mar 22 | 10,679 | 1,874 | 1,715 | 0 |
31 Dec 21 | 10,788 | 1,988 | 1,723 | 0 |
30 Sep 21 | 11,046 | 2,175 | 1,674 | 0 |
30 Jun 21 | 11,058 | 2,238 | 1,642 | 0 |
31 Mar 21 | 10,335 | 1,794 | 1,571 | 0 |
31 Dec 20 | 9,437 | 1,425 | 1,545 | 0 |
30 Sep 20 | 8,361 | 1,101 | 1,414 | 0 |
30 Jun 20 | 7,531 | 749 | 1,378 | 0 |
31 Mar 20 | 7,657 | 771 | 1,376 | 0 |
31 Dec 19 | 7,726 | 835 | 1,457 | 0 |
30 Sep 19 | 7,639 | 709 | 1,402 | 0 |
30 Jun 19 | 7,572 | 707 | 1,406 | 0 |
31 Mar 19 | 7,538 | 720 | 1,387 | 0 |
31 Dec 18 | 7,531 | 733 | 1,395 | 0 |
30 Sep 18 | 7,557 | 860 | 1,378 | 0 |
30 Jun 18 | 7,524 | 808 | 1,359 | 0 |
31 Mar 18 | 7,469 | 782 | 1,372 | 0 |
31 Dec 17 | 7,402 | 769 | 1,421 | 0 |
30 Sep 17 | 7,398 | 671 | 1,413 | 0 |
30 Jun 17 | 7,427 | 701 | 1,480 | 0 |
31 Mar 17 | 7,469 | 702 | 1,558 | 0 |
31 Dec 16 | 7,214 | 642 | 1,337 | 0 |
30 Sep 16 | 7,503 | 675 | 1,624 | 0 |
30 Jun 16 | 7,498 | 825 | 1,637 | 0 |
31 Mar 16 | 7,517 | 748 | 1,637 | 0 |
31 Dec 15 | 7,493 | 706 | 1,616 | 0 |
30 Sep 15 | 7,527 | 703 | 1,654 | 0 |
30 Jun 15 | 7,551 | 491 | 1,657 | 0 |
31 Mar 15 | 7,528 | 507 | 1,651 | 0 |
31 Dec 14 | 7,435 | 549 | 1,635 | 0 |
30 Sep 14 | 7,308 | 506 | 1,638 | 0 |
30 Jun 14 | 7,192 | 780 | 1,620 | 0 |
31 Mar 14 | 7,105 | 799 | 1,620 | 0 |
31 Dec 13 | 7,146 | 811 | 1,632 | 0 |
Kaliteli Kazançlar: DGX yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: DGX 'nin mevcut net kar marjları (8.8%) geçen yılın (8.2%) sinden daha yüksektir.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: DGX şirketinin kazançları son 5 yılda yılda 5.7% oranında azaldı.
Büyüme Hızlandırma: DGX 'un son bir yıldaki kazanç büyümesi ( 10.4% ) 5 yıllık ortalamasını (yıllık -5.7% ) aşıyor.
Kazançlar vs. Sektör: DGX geçen yılki kazanç büyümesi ( 10.4% ) Healthcare sektörünün 11.4% performansını geride bırakmadı.
Özkaynak Getirisi
Yüksek ROE: DGX 'nin Özsermaye Getirisi ( 12.9% ) düşük olarak değerlendiriliyor.